http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022364056-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b2b4ef3f4468650d208087cfa125416c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1f85af810578fac3d697eb58690a6f7c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-36 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0638 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0634 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 |
| filingDate | 2020-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0cda2507195478aae4152024ab21a98 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_589d950fe2ec6c0b0f0c7e27266bf5c0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c7fc1303263f0b63fb5a71413fdfe7f |
| publicationDate | 2022-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2022364056-A1 |
| titleOfInvention | Short-chain fatty acid pentanoate as enhancer for cellular therapy and anti-tumor therapy |
| abstract | The invention involves improving the cultivation of T cells by incubating them with short-chain fatty acid (SCFA) pentanoate after isolation from peripheral blood. The effect is that the cells are activated and the production of effector molecules is increased. This increases the chances of success of tumor therapy. This is illustrated by T-cells from mice that are transferred to mice with subcutaneous pancreatic tumors after the procedure. This type of cell treatment can be transferred to humans and the improved treatment of pancreatic cancer. We show in detail that the short-chain fatty acid (SCFA) pentanoate enhances the function of CD8+ cytotoxic T lymphocytes (CTLs). We show that Pentanoate promotes the core molecular signature of murine CD8+ CTLs. Pentanoate enhances anti-tumor activity of antigen-specific CTLs. Bacterial-derived SCFAs exhibit specific HDAC class I inhibitory activity. Pentanoate-producing bacteria enhance CD8+ T cell-mediated anti-tumor immune responses. |
| priorityDate | 2019-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 49.